{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:40:36Z","timestamp":1784299236989,"version":"3.55.0"},"update-to":[{"DOI":"10.1371\/journal.pntd.0006986","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,12,28]],"date-time":"2018-12-28T00:00:00Z","timestamp":1545955200000}}],"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T00:00:00Z","timestamp":1544745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007637","name":"Departamento Administrativo de Ciencia, Tecnolog\u00eda e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["222972553501"],"award-info":[{"award-number":["222972553501"]}],"id":[{"id":"10.13039\/100007637","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["D43 TW006589"],"award-info":[{"award-number":["D43 TW006589"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1U19AI129910-01"],"award-info":[{"award-number":["1U19AI129910-01"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"DOI":"10.1371\/journal.pntd.0006986","type":"journal-article","created":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T15:26:18Z","timestamp":1544801178000},"page":"e0006986","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":31,"title":["Interventions to treat cutaneous leishmaniasis in children: A systematic review"],"prefix":"10.1371","volume":"12","author":[{"given":"Andr\u00e9s","family":"Uribe-Restrepo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Cossio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur M.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"D\u00e1valos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0485-2919","authenticated-orcid":true,"given":"Mar\u00eda del Mar","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,12,14]]},"reference":[{"key":"ref1","article-title":"Leishmaniasis worldwide and global estimates of its incidence","author":"J Alvar","year":"2012","journal-title":"PLoS ONE"},{"key":"ref2","unstructured":"PAHO\/WHO. Leishmaniasis. Epidemiological Report of the Americas. [Internet]. PAHO; 2018. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/iris.paho.org\/xmlui\/handle\/123456789\/34856\" xlink:type=\"simple\">http:\/\/iris.paho.org\/xmlui\/handle\/123456789\/34856<\/ext-link>"},{"key":"ref3","first-page":"11","article-title":"Framework for action on cutaneous leishmaniasis in the Eastern Mediterranean Region 2014\u20132018","year":"2014","journal-title":"Framework for action on cutaneous leishmaniasis in the Eastern Mediterranean Region 2014\u20132018"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3855\/jidc.2939","article-title":"Children and cutaneous leishmaniasis: A clinical report and review","volume":"7","author":"P Layegh","year":"2013","journal-title":"J Infect Dev Ctries"},{"key":"ref5","article-title":"Pharmacokinetics of miltefosine in children and adults with cutaneous leishmaniasis","author":"MDM Castro","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"ref6","doi-asserted-by":"crossref","DOI":"10.1086\/524042","article-title":"Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru","volume":"46","author":"A Llanos-Cuentas","year":"2008","journal-title":"Clin Infect Dis"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4269\/ajtmh.2001.64.187","article-title":"Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimoniate for cutaneous leishmaniasis due to Leishmania Viannia species","volume":"64","author":"R Palacios","year":"2001","journal-title":"Am J Trop Med Hyg"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"e1656","DOI":"10.1371\/journal.pntd.0001656","article-title":"Prediction score for antimony treatment failure in patients with ulcerative leishmaniasis lesions","volume":"6","author":"C Valencia","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/cid\/cit102","article-title":"Increasing Failure of Miltefosine in the Treatment of Kala-azar in Nepal and the Potential Role of Parasite Drug Resistance, Reinfection, or Noncompliance","volume":"56","author":"S Rijal","year":"2013","journal-title":"Clin Infect Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1574-695X.2007.00311.x","article-title":"Immune response to leishmania: Paradox rather than paradigm","author":"P Tripathi","year":"2007","journal-title":"FEMS Immunology and Medical Microbiology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1086\/510860","article-title":"Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate","volume":"195","author":"A Cruz","year":"2007","journal-title":"J Infect Dis"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1128\/AAC.00292-12","article-title":"Optimal dosing of miltefosine in children and adults with visceral leishmaniasis","volume":"56","author":"TPC Dorlo","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/pharmaceutics3010053","article-title":"Factors and mechanisms for pharmacokinetic differences between pediatric population and adults","author":"E Fern\u00e1ndez","year":"2011","journal-title":"Pharmaceutics"},{"key":"ref14","author":"S Yaffe","year":"2000"},{"key":"ref15","article-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"JPT Higgins","year":"2011","journal-title":"The Cochrane Collaboration"},{"key":"ref16","first-page":"CD005067","article-title":"Interventions for Old World cutaneous leishmaniasis","author":"U Gonz\u00e1lez","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"ref17","first-page":"CD004834","article-title":"Interventions for American cutaneous and mucocutaneous leishmaniasis","author":"U Gonz\u00e1lez","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e61843","DOI":"10.1371\/journal.pone.0061843","article-title":"Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update","volume":"8","author":"L Reveiz","year":"2013","journal-title":"PLoS One"},{"key":"ref19","article-title":"Veritas Health Innovation"},{"key":"ref20","article-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses [Internet]","author":"GA Wells"},{"key":"ref21","first-page":"13","article-title":"Local application of diminazene aceturate: an effective treatment for cutaneous leishmaniasis?","volume":"72","author":"L Lynen","year":"1992","journal-title":"Ann Soc Belg Med Trop"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/infdis\/jir816","article-title":"Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children","volume":"205","author":"LC Rubiano","year":"2012","journal-title":"J Infect Dis"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4269\/ajtmh.2011.10-0155","article-title":"Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil","volume":"84","author":"A Chrusciak-Talhari","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"ref24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000912","article-title":"Miltefosine in the treatment of cutaneous leishmaniasis caused by leishmania braziliensis in Brazil: A randomized and controlled trial","volume":"4","author":"PR Machado","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"ref25","first-page":"4","article-title":"Rifampicin in cutaneous leishmaniasis\u2013a therapeutic trial in Saudi Arabia","volume":"16","author":"H. Jaffar","year":"2006","journal-title":"J Pakistan Assoc Dermatologists"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4269\/ajtmh.2009.80.172","article-title":"Efficacy of cryotherapy versus intralesional meglumine antimoniate (Glucantime) for treatment of cutaneous leishmaniasis in children","volume":"80","author":"P Layegh","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"539","DOI":"10.4269\/ajtmh.2011.10-0002","article-title":"Systemic meglumine antimoniate in acute cutaneous leishmaniasis: Children versus adults","volume":"84","author":"P Layegh","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"ref28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000432","article-title":"WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study","volume":"3","author":"A Ben Salah","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"e0005515","DOI":"10.1371\/journal.pntd.0005515","article-title":"Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study","volume":"11","author":"MDM Castro","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental Pharmacology\u2014Drug Disposition, Action, and Therapy in Infants and Children","volume":"349","author":"GL Kearns","year":"2003","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"ref31","first-page":"S112","article-title":"StaR child health: developing evidence-based guidance for the design, conduct, and reporting of pediatric trials","volume":"129","author":"L Hartling","year":"2012","journal-title":"Pediatrics. American Academy of Pediatrics"},{"key":"ref32","unstructured":"European Medicines Agency. Guideline on pharmaceutical development of medicines 10 for paediatric use. 2013; Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2013\/01\/WC500137023.pdf\" xlink:type=\"simple\">http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2013\/01\/WC500137023.pdf<\/ext-link>"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1542\/peds.2012-0055I","article-title":"Standard 6: Age Groups for Pediatric Trials","volume":"129","author":"K Williams","year":"2012","journal-title":"Pediatrics"},{"key":"ref34","first-page":"1","article-title":"Clinical Investigation of Medicinal Products in the Pediatric Population (E11)","year":"2000"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1542\/peds.2012-0055J","article-title":"Empirical Evaluation of Age Groups and Age-Subgroup Analyses in Pediatric Randomized Trials and Pediatric Meta-analyses","volume":"129","author":"DG Contopoulos-Ioannidis","year":"2012","journal-title":"Pediatrics"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"e2907","DOI":"10.1371\/journal.pntd.0002907","article-title":"Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults","volume":"8","author":"J Altcheh","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"ref37","article-title":"Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections","author":"CC Blyth","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"359","DOI":"10.4269\/ajtmh.12-0784","article-title":"Clinical and epidemiologic profile of cutaneous leishmaniasis in Colombian children: considerations for local treatment","volume":"89","author":"VM Blanco","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1111\/j.1651-2227.2009.01394.x","article-title":"Thiopental pharmacokinetics in newborn infants: a case report of overdose","volume":"98","author":"E Norman","year":"2009","journal-title":"Acta Paediatr"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1586\/ecp.11.43","article-title":"Innovative clinical trial design for pediatric therapeutics","volume":"4","author":"MM Laughon","year":"2011","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref41","article-title":"Promoting Safety of Medicines for Children","year":"2007","journal-title":"WHO"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"e2130","DOI":"10.1371\/journal.pntd.0002130","article-title":"Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis","volume":"7","author":"P Olliaro","year":"2013","journal-title":"PLoS Negl Trop Dis"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0006986","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,12,28]],"date-time":"2018-12-28T00:00:00Z","timestamp":1545955200000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pntd.0006986","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T20:15:10Z","timestamp":1588968910000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0006986"}},"subtitle":[],"editor":[{"given":"Dhafer","family":"Laouini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,12,14]]},"references-count":42,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,12,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0006986","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pntd.0006986","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,14]]}}}